Zamann Pharma Support logo

Siedlerstraße 7 | 68623 Lampertheim, Germany

info@zamann-pharma.com

Request an appointment now

“GMP vs ISO: Inspection Expectations and Compliance Interpretation in 2026

This article explains why ISO-certified pharmaceutical organizations still face GMP inspection findings, how regulators interpret GMP versus ISO in practice, and what inspection-driven quality oversight requires beyond certification to achieve true regulatory inspection readiness.
  • Blog, GxP, Quality Management System
GMP inspection findings versus ISO certification showing regulatory inspection readiness and pharmaceutical quality system maturity.

CSV vs Annex 11: Inspection Expectations and Compliance Differences in 2026

Inspection-driven analysis of CSV vs Annex 11 highlighting why validated computerized systems still trigger findings. This article explains regulatory expectations, common inspection gaps, and how governance, data integrity, and lifecycle control shape inspection outcomes in GMP environments
  • Blog, GMP, GxP
Computerized systems inspection checklist showing data integrity controls, audit trail review, and risk-based validation expectations under EU GMP Annex 11.

Terminal Sterilization in Pharmaceutical Manufacturing: Inspection Findings and Sterility Assurance Gaps in 2026

GMP inspections increasingly show that weaknesses in terminal sterilization signal broader sterility assurance governance gaps. This article explains how inspectors assess control systems, why validated cycles still fail scrutiny, and what manufacturers must demonstrate to reduce critical findings.
  • Blog, GxP
GMP inspectors reviewing sterilization cycle data during pharmaceutical manufacturing to assess bioburden control, sterility assurance level alignment, and contamination control strategy.

Cross Contamination in Pharmaceutical Manufacturing: Inspection Findings and Control Failures in 2026

Inspection-focused analysis of cross contamination in pharmaceutical manufacturing, explaining why regulators classify control failures as critical GMP findings and how weaknesses in segregation, cleaning validation, and flow design drive inspection outcomes.
  • Blog, GxP
Visual representation of contamination control strategy in pharmaceutical manufacturing, illustrating facility risks, cleaning validation effectiveness, material and personnel flow control, and inspection-driven regulatory expectations.

GMP vs cGMP: Inspection Differences and Compliance Impact in 2026

This article explains how regulators distinguish between GMP and cGMP during inspections, why “current” compliance matters, and how governance gaps lead to inspection findings. It provides practical insight for quality, manufacturing, and compliance leaders preparing for regulatory revie
  • Blog, GMP
Regulatory inspection reviewing manufacturing process control and quality governance in pharmaceutical operations

Good Manufacturing Practices (GMP): Inspection Expectations and Manufacturing Governance in 2026

This article explores how regulators assess manufacturing quality systems during inspections, why governance failures drive critical observations, and how structured oversight improves inspection readiness, reduces compliance risk, and supports consistent decision-making across pharmaceutical operations.
  • Blog, GxP
Pharmaceutical quality team reviewing manufacturing records as part of inspection readiness and quality system oversight.

CIOMS in Pharmacovigilance: Inspection Expectations and Expedited Safety Reporting Governance 2026

This article explains how regulators assess the Pharmacovigilance System Master File during inspections, where governance gaps create audit findings, and why clear accountability, traceability, and inspection readiness determine long-term regulatory confidence.
  • Blog, GxP
Pharmacovigilance professional reviewing safety documents to ensure data consistency in safety reports and traceable regulatory safety communication.

PBRER in Pharmacovigilance: Inspection Expectations and Benefit–Risk Governance in 2026

An inspection-driven overview explaining how regulators assess benefit–risk narratives in PBRERs, where governance gaps trigger repeat findings, and how structured oversight across reporting cycles strengthens compliance and regulatory confidence in pharmacovigilance systems.
  • Blog, GxP
Quality assurance team reviewing safety data as part of benefit risk assessment lifecycle and regulatory benefit–risk oversight.

DSUR in Pharmacovigilance: Inspection Expectations and 2026 Downloadable PDF

This article explains how regulators assess DSURs during clinical development, focusing on safety governance, benefit–risk assessment, and data consistency across trials. It highlights common inspection findings and shows how structured oversight reduces regulatory risk and inspection escalation.
  • Blog, GxP
Illustration showing sponsor safety governance, safety data integration across trials, and benefit–risk assessment during development aligned with developmental safety update report compliance.

PSMF in pharmacovigilance: Inspection Expectations, Governance, and Compliance Focus in 2026

This article explains how regulators assess the Pharmacovigilance System Master File during inspections, where governance gaps create audit findings, and why clear accountability, traceability, and inspection readiness determine long-term regulatory confidence.
  • Blog
Structured documentation and clear audit trails support pharmacovigilance system master file governance and inspection readiness.